Molecular diagnostic testing for primary biliary cholangitis

References

• Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Dalekos GN. Molecular diagnostics of primary biliary cirrhosis. Expert Opin Med Diagn. 2008;2:621–634.
   PubMedGoogle Scholar
• Floreani A, Caroli D, Variola A, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int. 2011;31:361–368.
   PubMed Web of Science ®Google Scholar
• European association for the study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267.
   PubMed Web of Science ®Google Scholar
• Metcalf J, Mitchinson H, Palmer J, et al. Natural history of early primary biliary cirrhosis. Lancet. 1996;348:1399–1402.
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Selmi C, Ranftler C, et al. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005;25:298–310.
   PubMed Web of Science ®Google Scholar
• Gatselis NK, Zachou K, Norman GL, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471–479.
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54:528–532.
   PubMed Web of Science ®Google Scholar
• Granito A, Muratori P, Quarneti C, et al. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn. 2012;12:65–74.
   PubMed Web of Science ®Google Scholar
• Norman GL, Yang CY, Ostendorff HP, et al. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2015;35:642–651.
   PubMed Web of Science ®Google Scholar
• Mells GF, Floyd JA, Morley KI, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43:329–332.
   PubMed Web of Science ®Google Scholar
• Bell LN, Wulff J, Comerford M, et al. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int. 2015;35:263–274.
   PubMed Web of Science ®Google Scholar
• Padgett KA, Lan RY, Leung PC, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun. 2009;32:246–253.
   PubMed Web of Science ®Google Scholar
• Mackay IR. Primary biliary cirrhosis showing a high titer of autoantibody; report of a case. N Engl J Med. 1958;258:185–188.
   PubMed Web of Science ®Google Scholar
• Gershwin ME, Mackay IR, Sturgess A, et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 1987;138:3525–3531.
   PubMed Web of Science ®Google Scholar
• Fussey SP, Guest JR, James OF, et al. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA. 1988;85:8654–8658.
   PubMed Web of Science ®Google Scholar
• Leung PS, Chol J, Yang G, et al. A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis. Expert Rev Mol Diagn. 2016;16:697–705.
   PubMed Web of Science ®Google Scholar
• Berg PA, Klein R. Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Liver. 1995;15:281–292.
   PubMedGoogle Scholar
• Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41:677–683.
   PubMed Web of Science ®Google Scholar
• Leung PSC, Manns MP, Coppel RL, et al. Detection of antimitochrondrial antibodies in primary biliary cirrhosis and LKM antibodies in autoimmune hepatitis. Manual of clinical laboratory immunology. 8th ed. Washington D.C.: ASM Press; 2016.
   Google Scholar
• Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis. 2004;1:2.
   PubMedGoogle Scholar
• Dalekos GN, Zachou K, Liaskos C, et al. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med. 2002;13:293–303.
   PubMedGoogle Scholar
• Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology. 1997;25:1090–1095.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Pelszynska M, Prokopowicz D, et al. High concetration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis. World J Gastroenterol. 2005;11:5706–5709.
   PubMed Web of Science ®Google Scholar
• Kuroda M, Morito T, Takagi T, et al. Antibodies to E1 and E2/Protein X components of pyruvate dehydrogenase complex in sera of patients with primary biliary cirrhosis. J Hepatol. 1996;25:867–6.
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Davies ET, Bogdanos DP, et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int. 2007;27:1226–1231.
   PubMed Web of Science ®Google Scholar
• Nishio A, Keeffe EB, Gershwin ME. Immunopathogenesis of primary biliary cirrhosis. Semin Liver Dis. 2002;22:291–302.
   PubMed Web of Science ®Google Scholar
• Moteki S, Leung PS, Coppel RL, et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology. 1996;24:97–103.
   PubMed Web of Science ®Google Scholar
• Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology. 2001;34:243–248.
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Gershwin ME, et al. True’ antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol. 2004;135:154–158.
   PubMed Web of Science ®Google Scholar
• Gabeta S, Norman GL, Liaskos C, et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol. 2007;27:378–387.
   PubMed Web of Science ®Google Scholar
• Dahnrich C, Pares A, Caballeria L, et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem. 2009;55:978–985.
   PubMed Web of Science ®Google Scholar
• Oertelt S, Rieger R, Selmi C, et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology. 2007;45:659–665.
   PubMed Web of Science ®Google Scholar
• Manns M, Gerken G, Kyriatsoulis A, et al. Two different subtypes of antimitochondrial antibodies are associated with primary biliary cirrhosis: identification and characterization by radioimmunoassay and immunoblotting. Hepatology. 1987;7:893–899.
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Bogdanos DP, Liaskos C, et al. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta. 2007;380:118–121.
   PubMed Web of Science ®Google Scholar
• Masuda J, Omagari K, Ohba K, et al. Correlation between histopathological findings of the liver and IgA class antibodies to 2-oxo-acid dehydrogenase complex in primary biliary cirrhosis. Dig Dis Sci. 2003;48:932–938.
   PubMed Web of Science ®Google Scholar
• Muratori L, Muratori P, Granito A, et al. The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Dig Liver Dis. 2005;37:108–112.
   PubMedGoogle Scholar
• Worman HJ. Nuclear envelope protein autoantigens in primary biliary cirrhosis. Hepatol Res. 2007;37(Suppl 3):S406–11.
   Google Scholar
• Invernizzi P, Podda M, Battezzati PM, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol. 2001;34:366–372.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118–127.
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Liaskos C, Pares A, et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology. 2007;45:1583–1584.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol. 2005;45:386–392.
   Web of Science ®Google Scholar
• Nakamura M, Kondo H, Tanaka A, et al. Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis. Hepatol Res. 2015;45:846–855.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Klima A, Komina O, et al. Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. Ann N Y Acad Sci. 2007;1109:519–530.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43:1135–1144.
   PubMed Web of Science ®Google Scholar
• Miyachi K, Hankins RW, Matsushima H, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun. 2003;20:247–254.
   PubMed Web of Science ®Google Scholar
• Szostecki C, Guldner HH, Will H. Autoantibodies against “nuclear dots” in primary biliary cirrhosis. Semin Liver Dis. 1997;17:71–78.
   PubMed Web of Science ®Google Scholar
• Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis. 1997;17:79–90.
   PubMed Web of Science ®Google Scholar
• Janka C, Selmi C, Gershwin ME, et al. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology. 2005;41:609–616.
   PubMed Web of Science ®Google Scholar
• Granito A, Yang WH, Muratori L, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:125–131.
   PubMed Web of Science ®Google Scholar
• Bauer A, Habior A, Kraszewska E. Detection of anti-SP100 antibodies in primary biliary cirrhosis. Comparison of ELISA and immunofluorescence. J Immunoassay Immunochem. 2013;34:346–355.
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Cassani F, et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol. 2002;127:172–175.
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Dalekos GN. Anti-sp100 antibodies in primary biliary cirrhosis. Scand J Gastroenterol. 2004;39:406–407.
   PubMed Web of Science ®Google Scholar
• Zuchner D, Sternsdorf T, Szostecki C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology. 1997;26:1123–1130.
   PubMed Web of Science ®Google Scholar
• Mytilinaiou MG, Meyer W, Scheper T, et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clin Chim Acta. 2012;13:1211–1216.
   Web of Science ®Google Scholar
• Granito A, Muratori P, Muratori L, et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;26:831–838.
   PubMed Web of Science ®Google Scholar
• Orton SM, Peace-Brewer A, Schmitz JL, et al. Practical evaluation of methods for detection and specificity of autoantibodies to extractable nuclear antigens. Clin Diagn Lab Immunol. 2004;11:297–301.
   PubMedGoogle Scholar
• Rigamonti C, Shand LM, Feudjo M, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2006;55:388–394.
   PubMed Web of Science ®Google Scholar
• Himoto T, Nakai S, Kinekawa F, et al. Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody. Dig Dis Sci. 2009;54:360–368.
   PubMed Web of Science ®Google Scholar
• Zachou K, Muratori P, Koukoulis GK, et al. Review article: autoimmune hepatitis – current management and challenges. Aliment Pharmacol Ther. 2013;38:887–913.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Komori A, Ito M, et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res. 2007;37(Suppl 3):S412–9.
   PubMed Web of Science ®Google Scholar
• Gao L, Tian X, Liu B, et al. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med. 2008;8:9–15.
   PubMed Web of Science ®Google Scholar
• Tozzoli R, Bonaguri C, Melegari A, et al. Current state of diagnostic technologies in the autoimmunology laboratory. Clin Chem Lab Med. 2013;51:129–138.
   PubMed Web of Science ®Google Scholar
• Liu H, Norman GL, Shums Z, et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436–442.
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Covini G, Rosina F, et al. Overcoming a “probable” diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. Clin Rev Allergy Immunol. 2012;42:288–297.
   PubMed Web of Science ®Google Scholar
• Villalta D, Sorrentino MC, Girolami E, et al. Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. Clin Chim Acta. 2015;438:135–138.
   PubMed Web of Science ®Google Scholar
• Hu CJ, Song G, Huang W, et al. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012;11:669–680.
   PubMed Web of Science ®Google Scholar
• Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127:485–492.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42:655–657.
   PubMed Web of Science ®Google Scholar
• Liu JZ, Almarri MA, Gaffney DJ, et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2012;44:1137–1141.
   PubMed Web of Science ®Google Scholar
• Carbone M, Lleo A, Sandford RN, et al. Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol. 2014;44:945–954.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Gershwin ME, Strauss R, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to Ursodeoxycholic Acid: a proof-of-concept study. Hepatology. 2015; Epub 2015 Nov 24. doi:10.1002/hep.28359.
   Web of Science ®Google Scholar
• Lian JS, Liu W, Hao SR, et al. A serum metabolomic analysis for diagnosis and biomarker discovery of primary biliary cirrhosis and autoimmune hepatitis. Hepatobiliary Pancreat Dis Int. 2015;14:413–421.
   PubMed Web of Science ®Google Scholar
• Tang YM, Wang JP, Bao WM, et al. Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis. Int J Mol Med. 2015;36:377–385.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Ikeda H, Yamaguchi J, et al. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence. Hepatology. 2008;48:186–195.
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet. 2004;363:533–535.
   PubMed Web of Science ®Google Scholar
• Zografos TA, Gatselis N, Zachou K, et al. Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. World J Gastroenterol. 2012;18:4721–4728.
   PubMed Web of Science ®Google Scholar
• Lleo A, Oertelt-Prigione S, Bianchi I, et al. Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun. 2013;41:87–91.
   PubMed Web of Science ®Google Scholar
• Hu Z, Huang Y, Liu Y, et al. beta-Arrestin 1 modulates functions of autoimmune T cells from primary biliary cirrhosis patients. J Clin Immunol. 2011;31:346–355.
   PubMed Web of Science ®Google Scholar
• Lleo A, Liao J, Invernizzi P, et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology. 2012;55:153–160.
   PubMed Web of Science ®Google Scholar
• Hrdlickova B, Kumar V, Kanduri K, et al. Expression profiles of long non-coding RNAs located in autoimmune disease-associated regions reveal immune cell-type specificity. Genome Med. 2014;6:88.
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Tozzoli R, Villalta D. Autoimmune diagnostics: the technology, the strategy and the clinical governance. Immunol Res. 2015;61:126–134.
   PubMed Web of Science ®Google Scholar
• Tozzoli R, Bizzaro N. The clinical autoimmunologist and the laboratory autoimmunologist: the two sides of the coin. Autoimmun Rev. 2012;11:766–770.
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Morozzi G. A proposed model for effective collaboration between rheumatologists and clinical pathologists for the diagnosis of autoimmune rheumatic diseases. Rheumatol Int. 2009;29:849–851.
   PubMed Web of Science ®Google Scholar